S.C. Pharma SRL
S.C. Pharma reported total assets of 52,882 € at the end of the 2025 financial year (annual accounts filed with the NBB on 17 Jun 2026).
The score of S.C. Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +9 % Total assets -44 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
S.C. Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 17 Jun 2026
- Year ended 31 Dec 2024filed on 26 Jun 2025
- Year ended 31 Dec 2023filed on 26 Jun 2024
- Year ended 31 Dec 2022filed on 28 Jun 2023
- Year ended 31 Dec 2021filed on 08 Jun 2022
S.C. Pharma's financial analysis
- Solvency70.4%sector median: 40.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of S.C. Pharma
S.C. Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0700.951.989
- VAT number
- BE0700951989
- Peppol
- Registered · 0208:0700951989 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 17 Aug 2018
- Registered office
- 7370 Dour
- Latest accounts
- 2025 · filed on 17 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
S.C. Pharma (SRL) has been based in Dour since 2018, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 1,401 € and equity of 37,206 €; its revenue is not published. Its solvency stands at 70.4%, above the median of its sector (40.1%).
Companies similar to S.C. Pharma
Companies in the same business, of comparable size and area, outside its group.
- Anfalis-Holding Retail sale of pharmaceutical products Koekelberg · balance sheet 56,888 €
- MB Pharmaceutics Retail sale of pharmaceutical products Riemst · balance sheet 57,363 €
- Pharmanatuur Retail sale of pharmaceutical products Affligem · balance sheet 51,561 €
- NZpharma Retail sale of pharmaceutical products Woluwe-Saint-Lambert · balance sheet 74,203 €
- Apotheker Laura Spiritus Retail sale of pharmaceutical products Linter · balance sheet 62,639 €
- Lotte Deroover Retail sale of pharmaceutical products Boortmeerbeek · balance sheet 39,701 €
- L.V. Farma Retail sale of pharmaceutical products Hasselt · balance sheet 83,799 €
- Manon De Marez Retail sale of pharmaceutical products Herent · balance sheet 85,130 €
Frequently asked questions about S.C. Pharma
What is the revenue of S.C. Pharma?
S.C. Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of S.C. Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0700951989 for S.C. Pharma, if the company is VAT-registered. Its company number (CBE) is 0700.951.989.
Where is the registered office of S.C. Pharma?
According to the CBE register, the registered office of S.C. Pharma is in 7370 Dour.
What is the equity of S.C. Pharma?
At the close of the 2025 financial year, the equity of S.C. Pharma amounts to 37,206 €, a solvency of 70.4% of total assets.
Who manages S.C. Pharma?
The register lists 1 active mandates at S.C. Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of S.C. Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →